FDA approves Pfizer's NGENLA™, a long-acting once-weekly treatment for pediatric growth hormone deficiency
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone.
Bayer's new pharmaceutical R&D strategy to accelerate breakthrough innovations
- Details
- Category: Bayer
This afternoon at 2 pm CET (8 am EDT), Bayer AG will host its Pharmaceuticals R&D Event 2023 for Investors. The company will present a deep dive on the innovation strategy in its four therapeutic core areas Oncology, Cardiovascular Diseases, Neurology & Rare Diseases and Immunology. The presentations will also include status updates on Bayer Pharmaceuticals' key assets in clinical and preclinical development as well as on its platform companies Asklepios BioPharmaceutical (AskBio), BlueRock Therapeutics (BlueRock) and Vividion Therapeutics (Vividion).
FDA accepts Pfizer's application for hemophilia B gene therapy fidanacogene elaparvovec
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) for fidanacogene elaparvovec for the treatment of adults with hemophilia B. In parallel, the European marketing authorization application (MAA) for fidanacogene elaparvovec has also been accepted and is under review by the European Medicines Agency (EMA).
FDA approves Pfizer's LITFULO™ (ritlecitinib) for adults and adolescents with severe alopecia areata
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved LITFULO™ (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age and older with severe alopecia areata. The approved recommended dose for LITFULO is 50 mg. It is the first and only treatment approved by the FDA for adolescents (12+) with severe alopecia areata.
Pfizer's TALZENNA® in combination with XTANDI® receives U.S. FDA approval
- Details
- Category: Pfizer
Pfizer (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved TALZENNA (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI (enzalutamide), for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Real-world evidence highlights the urgent need to act on the growing global burden of chronic kidney disease
- Details
- Category: AstraZeneca
AstraZeneca, a leader in cardiorenal diseases, presented new real-world evidence (RWE) data at the European Renal Association (ERA) 2023 Congress in Milan, Italy, demonstrating the staggeringly low rate of diagnosis in chronic kidney disease (CKD). These data show that an urgent need exists for improved screening which can lead to earlier diagnosis.
Results from the REVEAL-CKD multinational study showed that the prevalence of undiagnosed Stage 3 (moderate) CKD was 85% to 97% across Spain, Australia, Canada and Brazil.
Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology
- Details
- Category: Bayer
Bayer and Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, announced an exclusive license agreement to develop and commercialize Cedilla Therapeutics' CyclinE1/CDK2 complex inhibitors which selectively address oncogenic drivers.
Overexpression or genetic activation of Cyclin Dependent Kinase 2 (CDK2) binding partner cyclin E is a key oncogenic process in several cancers.
More Pharma News ...
- AstraZeneca announces agreement with Quell Therapeutics to develop, manufacture and commercialise engineered T-regulatory cell therapies for autoimmune diseases
- Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics
- New England Journal of Medicine publishes results from Phase 3 induction and maintenance programs evaluating upadacitinib (RINVOQ®) in Crohn's disease
- Insilico Medicine receives IND approval for novel AI-designed USP1 inhibitor for cancer
- U.S. FDA approves ABRYSVO™, Pfizer's vaccine for the prevention of respiratory syncytial virus (RSV) in older adults
- Bayer launches unit to develop new precision health consumer products
- Pfizer's PAXLOVID™ receives FDA approval for adult patients at high risk of progression to severe COVID-19